CD226 and neoplasm: The interaction between NK activating receptors, including NKG2D, NKG2C, DNAM-1, NCRs (NKp46, NKp44, and NKp30), and NKp80, with their corresponding ligands on tumor cells results in the activation of NK cells, leading to enhanced NK cell cytotoxicity (3–5).